SynthesisIranian biomedical journal2026
Translating Mesenchymal Stem Cell Research into Chronic Kidney Disease Therapy: A Systematic and Clinical Review.
Synthesis in Iranian biomedical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease (CKD) is a progressive disorder with high morbimortality and limited treatment options. Mesenchymal stem cells (MSCs) have emerged as a promising therapy because of their immunomodulatory and regenerative properties. This systematic review evaluates the therapeutic potential of MSC therapy for CKD by searching databases PubMed, Medline, Embase, the Cochrane Library, and Scopus from January 2000 to May 2026 using keywords “mesenchymal stem cells,” “cell therapy,” and “renal failure”. Among 1,525 identified studies, 19 met the inclusion criteria, covering preclinical and clinical investigations. Findings indicated contribution of MSC therapy to renal tissue repair, immunomodulation, and functional recovery, with some studies reporting improvements in glomerular filtration rate, reduced proteinuria, and histological recovery of kidney tissue. While the short-term safety profiles were favorable, the long-term efficacy and optimal administration protocols remain uncertain. Further high-quality clinical trials are needed to establish standardized treatment protocols and validate long-term benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.